

<b>Interview Summary</b>	<b>Application No.</b> 10/531,547	<b>Applicant(s)</b> KHOSLA ET AL.
	<b>Examiner</b> JACOB CHEU	<b>Art Unit</b> 1641

All participants (applicant, applicant's representative, PTO personnel):

(1) JACOB CHEU.  (3) \_\_\_\_\_.

(2) Ms. Sherwood.  (4) \_\_\_\_\_.

Date of Interview: 22 February 2010.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.

If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 23.


Identification of prior art discussed: Arentz-Hansen of record.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



/Jacob Cheu/  
Primary Examiner, Art Unit 1641

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant's representative commented that the Arentz-Hansen did not teach the SEQ ID No. 12 and they merely using a 14 mer peptide for their study. Applicant's invention is dependent on the antibody generated by this SEQ ID No. 12. Moreover, Applicant also submitted Xia et al. reference (JACS 206 Vol. 128,page 1859) indicating distinct property of the 14 mer vs. SEQ ID No.12 (seq 6 vs seq 1 in Table 1). Examiner would reconsider the merits and make decision accordingly. .